nach oben

Journal of Diabetes & Metabolic Disorders

Erschienen in:

20.05.2021 | Research article

Vitamin D3 attenuates oxidative stress and regulates glucose level and leukocyte count in a semi-chronic streptozotocin-induced diabetes model

verfasst von: Maja Mitrašinović-Brulić, Amela Dervišević, Asija Začiragić, Muhamed Fočak, Amina Valjevac, Almira Hadžović-Džuvo, Damir Suljević

Erschienen in: Journal of Diabetes & Metabolic Disorders | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Vitamin D3 (vit-D3) is a potent immunomodulator with anti-inflammatory and antioxidative properties. We used streptozotocin (STZ)-induced rat model of diabetes (DM) to evaluate the effects of vit-D3. We measured serum biochemical parameters, interleukin-17 (IL-17), osteocalcin (OC), malondialdehyde (MDA), and immune cell count on the 21st day of experiment.

Method

A total of 24 Wistar rats were randomly divided into three groups. Each group had eight rats. During the 1st day of the experiment, the control group was injected intraperitoneally with citrate buffer, while STZ group and STZ + vit-D3 group were injected by a single i.p. dose (35 mg/kg) of STZ dissolved in citrate buffer (pH 4,5; 0,1 M). Vitamin D3 was applied via oral gavage once daily to the STZ + vit-D3 group for a total period of 14 days, starting from the 7th day of the experiment.

Results

STZ rats showed a significant reduction in OC and an increase in MDA and IL-17 serum concentrations compared to the control rats. We also observed a significant STZ-associated decrease in the number of lymphocytes and a significant increase in monocyte and eosinophil number. Oral treatment with vit-D3 to STZ-induced diabetic rats significantly increased OC and decreased MDA serum levels. Furthermore, vit-D3 treatment resulted in a good regulation of hematopoiesis such as increase in the number of segmented granulocytes and lymphocytes and a reduction in the number of monocytes and eosinophils.

Conclusion

Vit-D3 treatment has important therapeutic effects; among many others it can attenuate oxidative stress and ameliorate the hyperglycemic state in the STZ-induced rat diabetic model, which is promising for further clinical trials.

Abdollahi M, Hosseini A. Streptozotocin. In: Phili W, editor. Encyclopedia of toxicology. 3rd ed. London: Academic; 2014. p. 402–4.CrossRef

Schein PS, Cooney DA, Vernon ML. The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity. Cancer Res. 1967;27:2324–32.PubMed

Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008;51:216–26. https://doi.org/10.1007/s00125-007-0886-7.CrossRefPubMed

Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen S. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin. Diabetologia. 2000;43:1528–33. https://doi.org/10.1007/s001250051564.CrossRefPubMed

Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50:537–46.PubMed

Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans. Circulation. 2002;106:2067–72. https://doi.org/10.1161/01.CIR.0000034509.14906.AE.CrossRefPubMed

Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000;67:291–300. https://doi.org/10.1016/s0024-3205(00)00622-6.CrossRefPubMed

Fernánde-Real JM, Broch M, Vendrell J, Gutiérrez C, Casamitjana R, Pugeat M, Richart C, Ricart W. Interleukin-6 gene poly-morphism and insulin sensitivity. Diabetes. 2000;49:517–20. https://doi.org/10.2337/diabetes.49.3.517.CrossRef

Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adiposetissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196–200. https://doi.org/10.1210/jcem.82.12.4450.CrossRefPubMed

10.

Manohar SM, Vaikasuvu SR, Deepthi K, Sachan A, Narasimha SR. An association of hyperglycemia with plasma malondialdehyde and atherogenic lipid risk factors in newly diagnosed Type 2 diabetic patients. J Res Med Sci. 2013;18:89–93.PubMedPubMedCentral

11.

Foroughi M, Maghsoudi Z, Askari G. The effect of vitamin D supplementation on blood sugar and different indices of insulin resistance in patients with non-alcoholic fatty liver disease (NAFLD). Iran J Nurs Midwifery Res. 2016;21:100–4. https://doi.org/10.4103/1735-9066.174759.CrossRefPubMedPubMedCentral

12.

Alvarez JA, Ashraf A. Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol. 2010;2010:351–85. https://doi.org/10.1155/2010/351385.CrossRef

13.

Martin T, Campbell RK. Vitamin D and diabetes. Diabetes Spectr. 2011;24:113–8. https://doi.org/10.2337/diaspect.24.2.113.CrossRef

14.

Kim MR, Jeong SJ. Relationship between Vitamin D level and lipid profile in non-obese children. Metabolites. 2019;9:125. https://doi.org/10.3390/metabo9070125.CrossRefPubMedCentral

15.

Akbarzadeh A, Norouzian D, Mehrabi MR, Jamshidi S, Farhangi A, Verdi AA, Mofidian SM, Rad BL. Induction of diabetes by Streptozotocin in rats. Indian J Clin Biochem. 2007;2:60–4. https://doi.org/10.1007/BF02913315.CrossRef

16.

Lee JH, Yang SH, Oh JM, Lee MG. Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J Pharm Pharmacol. 2010;62:1–23. https://doi.org/10.1211/jpp.62.01.0001.CrossRefPubMed

17.

Cruz B, Flores RJ, Uribe KP, Espinoza EJ, Spencer CT, Serafine KM, Nazarian A, O’Dell LE. Insulin modulates the strong reinforcing effects of nicotine and changes in insulin biomarkers in a rodent model of diabetes. Neuropsychopharmacol. 2019;44:1141–51. https://doi.org/10.1038/s41386-018-0306-3.CrossRef

18.

Von Hurst PR, Sonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient: a randomized, placebo-controlled trial. Br J Nutr. 2010;103:549–55. https://doi.org/10.1017/S0007114509992017.CrossRef

19.

Bourlon PM, Billaudel B, Faure-Dussert A. Influence of vitamin D3 deficiency and 1,25 dihydroxyvitamin D3 on de novo insulin biosynthesis in the islets of the rat endocrine pancreas. J Endocrinol. 1999;160:87–95. https://doi.org/10.1677/joe.0.1600087.CrossRefPubMed

20.

Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2007;92:2017–29. https://doi.org/10.1210/jc.2007-0298.CrossRefPubMed

21.

Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, Clarke A, Franco OH. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas. 2010;65:225–36. https://doi.org/10.1016/j.maturitas.2009.12.013.CrossRefPubMed

22.

Schwallenberg G. Vitamin D and diabetes: improvement of glycemic control with vitamin D₃ repletion. Can Fam Phys. 2008;54:864–6.

23.

Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79:820–5. https://doi.org/10.1093/ajcn/79.5.820.CrossRefPubMed

24.

Riachy R, Vandewalle B, Moerman E, Belaich S, Lukowiak B, Gmyr V, Muharram G, Conte JK, Pattou F. 1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis. 2006;11:151–9. https://doi.org/10.1007/s10495-006-3558-z.CrossRefPubMed

25.

Hu Z, Chen J, Sun X, Wang L, Wang A. Efficacy of vitamin D supplementation on glycemic control in type 2 diabetes patients: A meta-analysis of interventional studies. Medicine. 2019;98(14):e14970. https://doi.org/10.1097/MD.0000000000014970.CrossRefPubMedPubMedCentral

26.

El Khoury G, Mansour H, Kabbara W, Chamoun N, Attalah N, Salameh P. Hyperglycemia in hospitalized diabetic non-critically ill patients: Prevalence, correlates, management and nurses’ attitudes. Curr Diabetes Rev. 2018;15(2):133–40. https://doi.org/10.2174/1573399814666180119142254.CrossRef

27.

Arif S, Moore F, Marks K, Bouckenooghe T, Dayan CM. Peripheral and islet interleukin-17 pathway activation characterizes human autoimmune diabetes and promotes cytokine-mediated β-cell death. Diabetes. 2011;60:2112–29. https://doi.org/10.2337/db10-1643.CrossRefPubMedPubMedCentral

28.

Fatima N, Faisal SM, Zubair S, Ajmal M, Siddiqui SS, Moin S, Owais M. Role of pro-inflammatory cytokines and biochemical markers in the pathogenesis of type 1 diabetes: Correlation with age and glycemic condition in diabetic human subjects. PLoS ONE. 2016;11(8):e0161548. https://doi.org/10.1371/journal.pone.0161548.CrossRefPubMedPubMedCentral

29.

Mohammed FM, Pambuk CIA, Al-Kadh NA. Evaluation of interleukin 17 A level and lipid profile in diabetic female patients treated by Metformin and Glimepiride in Kirkuk City Iraq. Biomed Pharmacol J. 2019;12(4):1849–55. https://doi.org/10.13005/bpj/1815.CrossRef

30.

Zúñiga LA, Shen WJ, Joyce-Shaikh B, Pyatnova EA, Richards AG, Thom C, Andrade SM, Cua DJ, Kraemer FB, Butcher EC. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol. 2010;11:6947–59. https://doi.org/10.4049/jimmunol.1001269.CrossRef

31.

Xia Y, Chen H, Xiao H, Yang J, Li Z, Wang Y, Yang T, Wang B. Immune regulation mechanism of vitamin D level and IL-17/IL-17R pathway in Crohn’s disease. Exp Therapy Med. 2019;5:3423–8. https://doi.org/10.3892/etm.2019.7389.CrossRef

32.

Seckin D, Ilhan N, Ilhan N, Ertugrul S. Glycaemic control, markers of endothelial cell activation and oxidative stress in children with type 1 diabetes mellitus. Diabetes Res Clin Pract. 2006;73:191–7. https://doi.org/10.1016/j.diabres.2006.01.001.CrossRefPubMed

33.

Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. Am J Clin Nutr. 1993;57:715–24. https://doi.org/10.1093/ajcn/57.5.715S.CrossRef

34.

Firoozrai M, Nourbakhsh M, Razzaghy-Azar M. Erythrocyte susceptibility to oxidative stress and antioxidant status in patients with type 1 diabetes. Diabetes Res Clin Pract. 2007;77:427–32. https://doi.org/10.1016/j.diabres.2007.02.001.CrossRefPubMed

35.

Esterbauer H, Eckl P, Ortner A. Possible mutagens derived from lipids and lipid precursors. Mutat Res. 1990;238:223–33. https://doi.org/10.1016/0165-1110(90)90014-3.CrossRefPubMed

36.

Alatawi FS, Faridi UA, Alatawi MS. Effect of treatment with vitamin D plus calcium on oxidative stress in streptozotocin-induced diabetic rats. Saudi Pharma J. 2018;8:1208–13. https://doi.org/10.1016/j.jsps.2018.07.012.CrossRef

37.

Hwang YC, Jeong IK, Ahm KJ, Chung HY. Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin level. Osteoporosis Int. 2012;23:1337–42. https://doi.org/10.1007/s00198-011-1679-x.CrossRef

38.

Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456–69. https://doi.org/10.1016/j.cell.2007.05.047.CrossRefPubMedPubMedCentral

39.

Janghorbani M, Feskanich D, Willett WC, Hu F. Prospective study of diabetes and risk of hip fracture: the Nurses’ Health Study. Diabetes Care. 2006;29:1573–8. https://doi.org/10.2337/dc06-0440.CrossRefPubMed

40.

Fadini GP, de Kreutzenberg SV, Boscaro E, Albiero M, Cappellari R, Krankel N, Landmesser U, Toniolo A, Bolego C, Cignarella A, Seeger F, Dimmeler S, Zeiher A, Agostini C, Avogaro A. An unbalanced monocyte polarisation in peripheral blood and bone marrow of patients with type 2 diabetes has an impact on microangiopathy. Diabetologia. 2013;8:1856–66. https://doi.org/10.1007/s00125-013-2918-9.CrossRef

41.

Venneri MA, Giannetta E, Panio G, De Gaetano R, Gianfrilli D, Pofi R, Masciarelli S, Fazi F, Pellegrini M, Lenzi A, Naro F, Isidori AM. Chronic inhibition of PDE5 limits pro-inflammatory monocyte-macrophage polarization in streptozotocin-induced diabetic mice. PLoS One. 2015;10(5):e0126580. https://doi.org/10.1371/journal.pone.0126580.CrossRefPubMedPubMedCentral

42.

Min D, Brooks B, Wong J, Salomon R, Bao W, Harrisberg B, Twigg SM, Yue DK, McLennan SV. Alterations in monocyte CD16 in as-sociation with diabetes complications. Mediat Inflamm. 2021;2012:649083. https://doi.org/10.1155/2012/649083.CrossRef

43.

Muller YD, Golshayan D, Ehirchiou D, Wyss JC, Giovannoni L, Meier R, Serre-Beinier V, Puga Yung G, Morel P, Bühler LH, Seebach JD. Immunosuppressive effects of streptozotocin-induced diabetes result in absolute lymphopenia and a relative increase of T regulatory cells. Diabetes. 2011;60:2331–40. https://doi.org/10.2337/db11-0159.CrossRefPubMedPubMedCentral

44.

Nagaraju S, Bertera S, Funair A, Wijkstrom M, Trucco M, Cooper DKC, Bottino R. Streptozotocin-associated lymphopenia in cynomolgus monkeys. Islets. 2014;6(3):e944441. https://doi.org/10.4161/19382014.2014.944441.CrossRefPubMedPubMedCentral

45.

Stohr R, Federici M. Insulin resistance and atherosclerosis: convergence between metabolic pathways and inflammatory nodes. Biochem J. 2013;1:1–11. https://doi.org/10.1042/bj20130121.CrossRef

46.

Pifarre P, Gutierrez-Mecinas M, Prado J, Usero L, Roura-Mir C, Giralt M, Hidalgo J, Garcia A. Phosphodiesterase 5 in-hibition at disease onset prevents experimental autoimmune encephalomyelitis progression through immunoregulatory and neuroprotective actions. Experiment Neurol. 2014;251:58–71. https://doi.org/10.1016/j.expneurol.2013.10.021.CrossRef

47.

Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, Naldini L. Identification of proangiogenicTIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007;12:276–85. https://doi.org/10.1182/blood-2006-10-053504.CrossRef

Titel: Vitamin D3 attenuates oxidative stress and regulates glucose level and leukocyte count in a semi-chronic streptozotocin-induced diabetes model
verfasst von: Maja Mitrašinović-Brulić
Amela Dervišević
Asija Začiragić
Muhamed Fočak
Amina Valjevac
Almira Hadžović-Džuvo
Damir Suljević
Publikationsdatum: 20.05.2021
Verlag: Springer International Publishing
Erschienen in: Journal of Diabetes & Metabolic Disorders / Ausgabe 1/2021
Elektronische ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-021-00814-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Method

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Association of TNF-α-308 G>A (rs1800629) polymorphism with susceptibility of metabolic syndrome

Assessment of immune-alternations and their correlations with therapeutic outcomes of transplantation of autologous Mesenchymal and Allogenic fetal stem cells in patients with type 1 diabetes: a study protocol

Diabetes prevalence and mortality in COVID-19 patients: a systematic review, meta‐analysis, and meta‐regression

Diabetes and rhino-orbito-cerebral mucormycosis – A deadly duo

The rate of aerobic glycolysis is a pivotal regulator of tumor progression